Mark Tami L, Axelsen Kristen J, Mucha Lisa, Sadkova Yelena
Am J Manag Care. 2007 Jun;13 Suppl 3:S72-9.
The goal of this study was to examine prescription fill patterns of lipid-lowering agents among Medicare/ Medicaid dual-eligible patients by ethnicity.
Study data were obtained from the Thomson Medstat MarketScan Medicaid claims database. Medicare/Medicaid beneficiaries who filled prescriptions for lipid-lowering agents during 2003 were included in the study. Logistic regression models estimated the probability that beneficiaries, by ethnicity, switched to a different lipid-lowering medication, augmented therapy with another lipid-lowering agent, or titrated the dosage of the drug upward over the course of the year.
The models revealed that African Americans were less likely to switch lipid-lowering agents (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.60-0.78), augment lipid-lowering agents (OR, 0.53; 95% CI, 0.43-0.66), or titrate upward (OR, 0.75; 95% CI, 0.67-0.84) than whites.
These results suggest that African Americans may be receiving less aggressive treatment than other patients, which in turn may explain why many studies find that African Americans are less likely to reach lipid goals. These treatment disparities merit further study, because they may impact dual-eligible patients moving into Medicare Part D plans.
本研究的目的是按种族调查医疗保险/医疗补助双重资格患者中降脂药物的处方配药模式。
研究数据取自汤姆森医疗统计公司的医疗补助索赔数据库。2003年期间开具降脂药物处方的医疗保险/医疗补助受益人被纳入研究。逻辑回归模型估计了按种族划分的受益人在一年中换用不同降脂药物、增加另一种降脂药物治疗或提高药物剂量的概率。
模型显示,非裔美国人更换降脂药物的可能性较小(比值比[OR],0.68;95%置信区间[CI],0.60 - 0.78),增加降脂药物的可能性较小(OR,0.53;95% CI,0.43 - 0.66),或提高剂量的可能性较小(OR,0.75;95% CI,0.67 - 0.84),低于白人。
这些结果表明,非裔美国人可能比其他患者接受的治疗力度较小,这反过来可能解释了为什么许多研究发现非裔美国人达到血脂目标的可能性较小。这些治疗差异值得进一步研究,因为它们可能影响符合双重资格的患者加入医疗保险D部分计划。